216 related articles for article (PubMed ID: 22842103)
1. Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method.
Gupta LK
Spectrochim Acta A Mol Biomol Spectrosc; 2012 Nov; 97():495-501. PubMed ID: 22842103
[TBL] [Abstract][Full Text] [Related]
2. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
[TBL] [Abstract][Full Text] [Related]
3. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets.
Kadav AA; Vora DN
J Pharm Biomed Anal; 2008 Sep; 48(1):120-6. PubMed ID: 18583084
[TBL] [Abstract][Full Text] [Related]
4. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
5. Identification, synthesis and quantification of process-related impurities in auraptene.
Li YG; Chen HF; Tu MZ; Zhang PZ; Wang XY; Yuan JB; Yang WL
J Pharm Biomed Anal; 2011 Sep; 56(2):191-9. PubMed ID: 21705169
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe.
Goel A; Baboota S; Sahni JK; Srinivas KS; Gupta RS; Gupta A; Semwal VP; Ali J
J Chromatogr Sci; 2013 Mar; 51(3):222-8. PubMed ID: 22865836
[TBL] [Abstract][Full Text] [Related]
7. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
[TBL] [Abstract][Full Text] [Related]
8. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets.
Ertürk S; Sevinç Aktaş E; Ersoy L; Fiçicioğlu S
J Pharm Biomed Anal; 2003 Dec; 33(5):1017-23. PubMed ID: 14656592
[TBL] [Abstract][Full Text] [Related]
9. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
[TBL] [Abstract][Full Text] [Related]
10. Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase.
Stanisz B; Kania L
Acta Pol Pharm; 2006; 63(6):471-6. PubMed ID: 17438862
[TBL] [Abstract][Full Text] [Related]
11. A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets.
Mohammadi A; Rezanour N; Ansari Dogaheh M; Ghorbani Bidkorbeh F; Hashem M; Walker RB
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 846(1-2):215-21. PubMed ID: 17010681
[TBL] [Abstract][Full Text] [Related]
12. Isolation and structure determination of oxidative degradation products of atorvastatin.
Kracun M; Kocijan A; Bastarda A; Grahek R; Plavec J; Kocjan D
J Pharm Biomed Anal; 2009 Dec; 50(5):729-36. PubMed ID: 19615842
[TBL] [Abstract][Full Text] [Related]
13. A novel reverse phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine drug substance and drug product.
Malati V; Reddy AR; Mukkanti K; Suryanarayana MV
Talanta; 2012 Aug; 97():563-73. PubMed ID: 22841123
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.
Joseph L; George M; Rao B VR
Pak J Pharm Sci; 2008 Jul; 21(3):282-4. PubMed ID: 18614425
[TBL] [Abstract][Full Text] [Related]
15. LC determination of glimepiride and its related impurities.
Khan MA; Sinha S; Vartak S; Bhartiya A; Kumar S
J Pharm Biomed Anal; 2005 Oct; 39(5):928-43. PubMed ID: 16040224
[TBL] [Abstract][Full Text] [Related]
16. Isolation, structure characterization and quantification of related impurities in asperosaponin VI.
Ji D; Liu YF; Wang QH; Zhang CF; Yang ZL
Chin J Nat Med; 2013 Jul; 11(4):419-26. PubMed ID: 23845554
[TBL] [Abstract][Full Text] [Related]
17. Determination and characterization of degradation products of anastrozole by LC-MS/MS and NMR spectroscopy.
Sitaram C; Rupakula R; Reddy BN
J Pharm Biomed Anal; 2011 Dec; 56(5):962-8. PubMed ID: 21890298
[TBL] [Abstract][Full Text] [Related]
18. In situ assessment of atorvastatin impurity using MALDI mass spectrometry imaging (MALDI-MSI).
Rodrigues LR; de Oliveira DN; Ferreira MS; Catharino RR
Anal Chim Acta; 2014 Mar; 818():32-8. PubMed ID: 24626400
[TBL] [Abstract][Full Text] [Related]
19. A validated stability indicating ultra performance liquid chromatographic method for determination of impurities in Esomeprazole magnesium gastro resistant tablets.
Nalwade SU; Reddy VR; Rao DD; Morisetti NK
J Pharm Biomed Anal; 2012 Jan; 57():109-14. PubMed ID: 21920688
[TBL] [Abstract][Full Text] [Related]
20. Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC-MS, IR and NMR.
Liu L; Cao N; Ma X; Xiong K; Sun L; Zou Q; Yao L
J Pharm Biomed Anal; 2016 Jan; 117():325-32. PubMed ID: 26412721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
